Next-generation platforms poised to redefine crowded HAE landscape - Pharmaceutical Technology

The HAE pharmaceutical landscape is set for unprecedented expansion as a large proportion of pipeline drugs are found in Phase III. The HAE pharmaceutical landscape is set for unprecedented expansion as a large proportion of pipeline drugs are found in Phase III. Emerging technologies such as CRISPR and siRNA platforms may provide meaningful differentiation in an otherwise competitive landscape. HAE is a potentially life-threatening inherited disease characterised by recurrent and severe episodes of swelling in various parts of the body. Credit: sciencepics via Shutterstock.com. The hereditary angioedema (HAE) pharmaceutical landscape is evolving at an unprecedented speed. Following a surge of…

Source: Pharmaceutical Technology